›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Nina Kjellson


General Partner

"If you’re committed to advancing the quality and availability of medical care, you and I share a common objective. I’m looking for entrepreneurs that are changing the face of health care by combining vision and innovation with sound planning and leadership."

InterWest Team

Current Investments

Prior Investments

Nina's bio

Company News


Nina's Latest Buzz

Nina's video


Nina has been part of InterWest's healthcare team since 2002, investing in biopharmaceuticals and healthcare IT. Nina has a particular interest in the transformation of the U.S. healthcare system and invests in opportunities that serve high unmet medical needs and align with improved health outcomes at lower cost. 

She is a board member of Alvine PharmaceuticalsCidera Therapeutics (NASDAQ: CDTX), Eiger BiopharmaceuticalsLyceraOcera (NASDAQ: OCRX) and Welltok. Nina led InterWest's investment in Alt12 and co-sponsored InterWest's investment in TESARO (TSRO). She also is co-chair of ConsumerMed.org, a forum to address the convergence of healthcare and consumer innovation, and serves as a mentor to the Nike+ Accelerator and to Blueprint Health.

Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.

Nina received a B.A. in human biology from Stanford University with a focus on health policy and bioethics.

Prior Investments

Aspreva Pharmaceuticals (IPO 2006, ASPV), CNS Therapeutics (Acquired by Covidien in 2012), Fluidigm (IPO 2011, FLDM), Labrys Biologics (Acquired by Teva Pharmaceuticals, TEVA, in 2014), NovaCardia (Acquired by Merck in 2007), Trius Therapeutics (TSRX; acquired by Cubist in 2013)



I've always known that my career would focus on medicine and the life sciences as I am committed to advancing health care technologies and improving access to care. At InterWest, I aim to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of health care.

Nina Kjellson

Information Technology

Facebook Google+ Twitter Email LinkedIn Share